Darolutamide FDA Approval 2025: Prostate Cancer mCSPC Data
Discover the significance of the Darolutamide FDA Approval 2025 and how it advances prostate cancer care for patients.
Discover the significance of the Darolutamide FDA Approval 2025 and how it advances prostate cancer care for patients.
Peer-to-peer prior authorization challenges in breast cancer treatment, focusing on lymphedema prevention and its impact on oncology care and patients.
Learn how CDK4/6 inhibitors like abemaciclib and ribociclib fight hormone therapy resistance in HR+/HER2- breast cancer. Insights from monarchE and NATALEE trials.
Learn how sensation-preserving mastectomies enhance recovery with insights from Dr. Anne Peled. Explore safety and benefits.
New breast cancer treatment study shows no need for radiation after chemo success. Learn how this changes care.
Explore the 2025 I-SPY2 Trial’s breakthrough in breast cancer treatment for lobular carcinoma and MammaPrint improve outcomes.
Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron,…
Guide to post-CDK4/6 inhibitor treatment for HR+/HER2- breast cancer. Learn resistance, therapies, and access with ASCO expertise.
Discover insights from the MATTERHORN trial, showcasing the impact of durvalumab combined with FLOT chemotherapy.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.